Medicine and Healthcare
Starrag’s New Bumotec Machine Picks Through the Bones of Complex Manufacturing
HEBRON, Ky., May 2, 2023 (Newswire.com) - With 12 different variants built upon a single platform, the new Starrag Bumotec 191neo is a multi-axis mill/turn center that introduces a world of flexible and highly productive machining solutions. At the OMTEC exhibition, the Starrag Bumotec 191neo will be demonstrating just how flexible, productive and capable a machine it is with the one-hit production of a bone plate. Manufactured in volume throughout the medical industry, bone plates are particularly challenging to machine - but not for the Starrag Bumotec 191neo.
For manufacturers in the medical profession, the difficulty when producing bone plates is the ability to machine and subsequently finish the plates on all six sides in a single operation whilst striving for optimized cycle times and lights-out 24/7 production. On the booth at OMTEC, the machine will feed a 1.2-inch (30 mm) diameter titanium bar into the work envelope and deploy 20 different cutting tools to 26 operations to finish machine the bone plate in under 20 minutes. The challenge, as a medical device manufacturer would appreciate, is the complex machining of a long part between two stations whilst retaining perfect synchronization. Not only does the new Starrag Bumotec 191neo productively achieve this by machining the bone plates from bar stock in its robust work envelope, but it eradicates any requirement for secondary operations.
The epitome of high-end machining, the Starrag Bumotec 191neo will machine the bone plate at OMTEC in a single operation with impeccable surface finishes, leaving a part that is burr-free and free of tabs - and then delicately placing the parts into a collection receptacle for complete unmanned production. With such stringent regulations in the medical industry, machining bone plates with absolute confidence and quality conformity whilst delivering a completely automated production cell is exactly why manufacturers need to see the Starrag Bumotec 191neo at OMTEC.
The impressive new Starrag Bumotec 191neo is available in four versions, the 'P' with vice, 'PRM' with a multi-purpose pickup vice, the 'R' with a back-working spindle and the 'RP' with a combined vice and back-working spindle. Providing a choice of bar capacities of 1.7, 2, 2.6 inch (42, 50 or 65 mm), manufacturers can choose one of 12 machine configurations that are all based upon the same rigid and extremely robust.
Maintaining unparalleled thermal and performance stability during production, the Starrag Bumotec 191neo offers a formidable level of productivity. Compared to previous models, the new machine has a new tool change system that reduces changeovers by more than 15%. The machine also has a new milling spindle with increased torque and a back-working movement that is controlled by an electric motor. This combination provides the perfect blend of high-speed cutting with the power and rigidity for increased material removal rates whilst enhancing positional control.
The high-performance Starrag spindle is fed cutting tools from its 90-position tool magazine that now has an integrated tool breakage probe to support lights-out production runs. Further advancing the automation credentials of the new machine is the option of a traditional Bumotec palletizer or a robotic, modular or custom-made automated cell that delivers true '24/7' production, which is only interrupted by preventive maintenance when required. If you want to optimize your productivity with a completely flexible solution that can undertake the machining of a diverse range of component types, please come and visit Booth 447 at the OMTEC show in June.
Contact Information:Elena Schmidt-Schmiedebach
Marketing Manager North America, Canada and Mexico
[email protected]
+18593802356
Original Source: Starrag's New Bumotec Machine Picks Through the Bones of Complex Manufacturing
As Baseball Season Begins With New Rules, ZetrOZ Systems’ sam Technology is Critical for Mitigating Injury Risk
TRUMBULL, Conn., April 28, 2023 (Newswire.com) - Baseball is back, which means balls and strikes, hits and homers - and hamstring injuries. Studies show baseball's most common injury, hamstring tendon tears, is more prevalent in the season's first weeks, as is a common elbow injury. And this spring, both could become more frequent as rule changes reduce players' recovery time between pitches and plays. One way to mitigate the risks of these injuries is ZetrOz Systems' sustained acoustic medicine sam® device, which effectively treats soft-tissue injuries and can help players stay on the diamond.
The ZetrOZ sam® X1 and 2.0 devices are the only FDA-cleared wearable ultrasound units approved for daily home use. The low-intensity, long-duration ultrasound technology expedites the injury healing process without invasive surgery or potentially addictive painkillers and is clinically proven by more than 40 studies to reduce pain and improve function.
"We work with medical professionals nationwide, from orthopedic surgeons to athletic trainers, and they have used sam® to successfully treat thousands of professional and amateur athletes," said Dr. George Lewis, founder and CEO of ZetrOZ Systems. "We know those injuries are more likely to occur at the start of a season, especially in baseball, and our technology can help mitigate risk and improve healing of those injuries."
Several studies document the prevalence of injuries early in a season. A 2019 study in The Orthopaedic Journal of Sports Medicine used six years of Major League Baseball's own injury tracking database to examine trends in hamstring injuries, which it found was the most common injury in baseball.
"In various professional sports leagues (NFL, NBA, MLB), hamstring strains have been found to occur earlier in the season. Our study found similar results, with the highest number of hamstring sprains in April and May," the authors reported. "These factors may have an association with poor conditioning at the start of the season."
About 40 percent of hamstring injuries occur in April and May, the analysis found. The rate of hamstring strains in Major League Baseball increased from one injury every 39 games in 2011 to one in every 30 games in 2016, with a similar trend in minor league baseball.
The pattern was the same in injuries to the elbow's ulnar collateral ligament (UCL), according to a 2021 report from the Journal of Shoulder and Elbow Surgery, with April and May as peak months for UCL injuries. They also found that injuries within the first 90 days of the season were more severe, more commonly requiring surgery to repair them.
"Throwing athletes may have increased risk for an elbow injury at the start of the season because they have not attained midseason levels of muscle strength and endurance," the authors wrote. They also found that pitchers' shoulders had less range of motion early in the season, likely making them more vulnerable to injury.
Some observers fear injuries will be more common this year, with Major League Baseball now using a pitch clock that requires pitchers to throw to the batter within 15 seconds, or 20 seconds with a runner on base. That means pitchers have less recovery time between pitches, and batters have less recovery from swings or from running out foul balls.
A 2016 study in the Journal of Sports Science modeled the effects of the shorter rest period on pitching. The authors found that players would have more fatigue in the forearm muscles that stabilize the elbow, "increasing strain on the ulnar collateral ligament (UCL) and possibly increasing injury risk."
Treatment with ZetrOZ's sam® technology effectively treats injuries to tendons of the leg, elbow and other areas of the body. Among many studies demonstrating the system's efficacy, a 2015 level 4 clinical study by sports medicine experts at The Ohio State University and Duke University found sustained acoustic medicine delivered via ZetrOZ's sam® reduced pain and improved strength in patients' medial/lateral elbow tendons and Achilles' tendons.
Sustained acoustic medicine works by increasing blood vessel diameters to improve blood flow. That increases oxygenated hemoglobin at the site of the therapy and removes cytokine enzymes and cellular waste, with a result of more rapid healing and reduced pain.
"We know from our relationships with trainers across professional and college sports, as well physicians treating recreational athletes, that sam® heals athletes' soft-tissue injuries more rapidly and helps players stay on the field or return to it more quickly," Lewis said. "As baseball season begins and teams adapt to this new environment, sam® is available to help players stay healthy and on the diamond doing what they love."
ZetrOZ Systems' sam® technology was developed in part with funding from the National Institute of Health, National Science Foundation, Department of Defense and NASA. ZetrOZ Systems products are designed and manufactured in the United States and are protected by 46 U.S. patents.
To learn more, visit www.samrecover.com.
About ZetrOZ Systems
ZetrOZ Systems is leading healing innovations in sports medicine, developing wearable bioelectronic devices for the delivery of sustained acoustic medicine (sam®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of +46 patents and is the exclusive manufacturer and developer of the sam® product line, which is designed for the treatment of acute and chronic musculoskeletal conditions.
Contact Information:Maria Penaloza
[email protected]
Original Source: As Baseball Season Begins With New Rules, ZetrOZ Systems' sam Technology is Critical for Mitigating Injury Risk
h2o Therapeutics Announces Collaboration With AmerisourceBergen to Support the Commercialization of Apple Watch-Based App Parky for Parkinson’s Disease
ANKARA, Turkey & CONSHOHOCKEN, Penn., April 28, 2023 (Newswire.com) - Digital health start-up h2o Therapeutics today announced a collaboration with global healthcare company AmerisourceBergen to support the commercialization of Parky, a prescription mobile app cleared by the U.S. Food and Drug Administration (FDA) for monitoring certain symptoms in adults with Parkinson's Disease.
The Parky app, which is compatible with the Movement Disorder API developed by Apple Inc., monitors symptoms such as tremors and dyskinesia in real time via the use of Apple Inc.'s Apple Watch. It is a direct-to-patient tool for sharing meaningful and reliable data between patients and medical professionals regarding the course of the disease. As part of a pilot arrangement, AmerisourceBergen will facilitate patient engagement and health system integration services as part of its DTx Connect solution.
"Following the recent FDA clearance, we continue to focus on strategies and solutions that will enable us to expand patient access to Parky," said Yagmur Selin Gulmus, the founder of h2o Therapeutics. "Through this arrangement with AmerisourceBergen, our goal is to reduce barriers along the patient journey, improve access and expand our commercial reach. In support of the Parkinson's Disease community, we are proud to launch our patient-oriented technology during Parkinson's Awareness Month."
"Digital therapeutics offer tremendous potential, but developers face unique challenges that can affect market access and product potential," said Alex Kilgore, PharmD, Product Manager, Global Products and Solutions at AmerisourceBergen. "We look forward to supporting h2o Therapeutics and will leverage our digital health capabilities to help patients start on the Parky app following a prescription."
Parkinson's Disease, the fastest-growing neurological disorder, affects more than 10 million people worldwide, including about one million people in the United States, according to the Parkinson's Foundation. The Parky App aims to help healthcare providers develop a profile of the patient in daily life, bridging the gap between real-life and in-clinic settings.
AmerisourceBergen offers a wide range of services to support DTx developers and biopharmaceutical companies across the commercialization journey, including market access consulting, distribution and patient support services. The company in 2022 announced its plans to develop and launch DTx Connect, a cloud-based, fully integrated ordering, dispensing, and fulfillment platform that aims to facilitate patient access to physician-ordered digital therapeutics and digital diagnostics.
"During Parkinson's Awareness Month, AmerisourceBergen could not be prouder to stand together with Parkinson's Disease patients, their families and healthcare providers, and innovative digital health technology developers like h2o Therapeutics to support the best patient care," said Jason Dinger, Senior Vice President of Global Products and Solutions at AmerisourceBergen.
About h2o Therapeutics
h2o Therapeutics is developing digital therapeutics with a focus on wearable technologies, Augmented Reality (AR), and Artificial Intelligence (AI). h2o intends to make real-time human data become a handy tool for disease management in certain therapeutic areas. Our core understanding of digital therapeutics lies in the power of AI, the robustness of their clinical health research, and high levels of user engagement. Parky, a Parkinson's Disease prescription mobile app, received 510(k) clearance from the FDA in 2022.
About AmerisourceBergen
AmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more at www.amerisourcebergen.com.
Contact Information:Yagmur Selin Gulmus
Founder
[email protected]
Hande Erciyes
Operations Manager
[email protected]
Original Source: h2o Therapeutics Announces Collaboration With AmerisourceBergen to Support the Commercialization of Apple Watch-Based App Parky for Parkinson's Disease
